# Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers

> **NCT03205358** · PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 188 (actual)

## Conditions studied

- Meningitis
- Meningococcal Meningitis
- Meningococcal Infections

## Interventions

- **BIOLOGICAL:** Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
- **BIOLOGICAL:** Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine

## Key facts

- **NCT ID:** NCT03205358
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-31
- **Primary completion:** 2015-08-19
- **Final completion:** 2015-08-19
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2022-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03205358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03205358, "Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03205358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*